MA33297B1 - Production de nanoparticules encapsulées à des fractions volumiques élevées - Google Patents

Production de nanoparticules encapsulées à des fractions volumiques élevées

Info

Publication number
MA33297B1
MA33297B1 MA34384A MA34384A MA33297B1 MA 33297 B1 MA33297 B1 MA 33297B1 MA 34384 A MA34384 A MA 34384A MA 34384 A MA34384 A MA 34384A MA 33297 B1 MA33297 B1 MA 33297B1
Authority
MA
Morocco
Prior art keywords
biologically active
production
coated nanoparticles
compositions
methods
Prior art date
Application number
MA34384A
Other languages
Arabic (ar)
English (en)
Inventor
Aaron Dodd
Felix Meiser
Adrian Russell
Marck Norret
H William Bosch
Original Assignee
Iceutica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009901744A external-priority patent/AU2009901744A0/en
Application filed by Iceutica Pty Ltd filed Critical Iceutica Pty Ltd
Publication of MA33297B1 publication Critical patent/MA33297B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/18—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic using a vibrating apparatus
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
    • B02C17/14—Mills in which the charge to be ground is turned over by movements of the container other than by rotating, e.g. by swinging, vibrating, tilting
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
    • B02C17/18—Details
    • B02C17/20—Disintegrating members

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

La présente invention concerne des procédés de production de particules d'une matière biologiquement active qui fait appel à des processus de broyage à sec, ainsi que des compositions comprenant de telles matières, des médicaments produits au moyen desdites matières biologiquement actives sous forme particulaire et/ou des compositions, et concerne des méthodes de traitement d'un animal, y compris l'homme, au moyen d'une quantité thérapeutiquement efficace desdites matières biologiquement actives administrées à l'aide desdits médicaments.
MA34384A 2009-04-24 2010-04-23 Production de nanoparticules encapsulées à des fractions volumiques élevées MA33297B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17227809P 2009-04-24 2009-04-24
AU2009901744A AU2009901744A0 (en) 2009-04-24 Production of Encapsulated Nanoparticles at High Volume Fractions
PCT/AU2010/000464 WO2010121320A1 (fr) 2009-04-24 2010-04-23 Production de nanoparticules encapsulées à des fractions volumiques élevées

Publications (1)

Publication Number Publication Date
MA33297B1 true MA33297B1 (fr) 2012-05-02

Family

ID=43010603

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34384A MA33297B1 (fr) 2009-04-24 2010-04-23 Production de nanoparticules encapsulées à des fractions volumiques élevées

Country Status (21)

Country Link
US (5) US20120165410A1 (fr)
EP (2) EP3338766A1 (fr)
JP (2) JP6141012B2 (fr)
KR (3) KR101848766B1 (fr)
CN (2) CN102438593A (fr)
AP (1) AP3138A (fr)
AU (1) AU2010239159C1 (fr)
BR (1) BRPI1014878A2 (fr)
CA (1) CA2759102A1 (fr)
CO (1) CO6470805A2 (fr)
DK (1) DK2421509T3 (fr)
EA (1) EA201171279A1 (fr)
IL (2) IL254370B2 (fr)
MA (1) MA33297B1 (fr)
MX (1) MX356518B (fr)
MY (1) MY159098A (fr)
NZ (1) NZ595973A (fr)
SG (1) SG175309A1 (fr)
UA (1) UA110322C2 (fr)
WO (1) WO2010121320A1 (fr)
ZA (1) ZA201108651B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014MN00380A (fr) 2006-06-30 2015-06-19 Iceutica Pty Ltd
EP2421513B1 (fr) 2009-04-24 2017-12-13 Iceutica Pty Ltd. Nouvelle formulation d'indométhacine
EP2421530B1 (fr) * 2009-04-24 2019-08-21 Iceutica Pty Ltd. Formulation de métaxalone
NZ595984A (en) * 2009-04-24 2014-04-30 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
MY179872A (en) * 2009-04-24 2020-11-18 Iceutica Pty Ltd Method for the production of commercial nanoparticle and microparticle powders
MA33299B1 (fr) * 2009-04-24 2012-05-02 Iceutica Pty Ltd Nouvelle formulation de naproxène
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
SI2568988T1 (sl) * 2010-05-11 2016-10-28 Janssen Pharmaceutica N.V. Farmacevtske formulacije, obsegajoče 1-(beta-D-glukopiranozil)-2-tienilmetilbenzenske derivate kot inhibitorje SGLT
WO2012140120A1 (fr) 2011-04-13 2012-10-18 Janssen Pharmaceutica Nv Procédé de préparation de composés utiles en tant qu'inhibiteurs de sglt2
EP2712628B1 (fr) 2012-09-28 2016-08-10 Shanta Banerjee Composition destinée à être utilisée en tant que médicament ou aliment diététique, en particulier dans la prévention et/ou le traitement du diabète et de maladies associées au diabète
JP2016508447A (ja) * 2013-02-28 2016-03-22 サン・ケミカル・コーポレーション 連続的微細メディア含有粉砕プロセス
JP6453876B2 (ja) * 2013-07-22 2019-01-16 イシューティカ インコーポレイテッド メタキサロンの製剤
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
ES2542088B1 (es) * 2014-01-29 2016-05-05 Enoc Solutions, S.L. Composición de azufre liposomado
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CN104174468B (zh) * 2014-08-27 2016-06-15 上海延安药业有限公司 粘稠性药物锆珠研磨方法
US10519039B2 (en) * 2015-05-20 2019-12-31 Universite Pierre Et Marie Curie (Paris 6) Mechanochemical process for the production of BP, B12P2 and mixtures thereof, in particular as nanopowders
US10154947B2 (en) 2016-01-06 2018-12-18 The Procter & Gamble Company Antiperspirant composition
US9730867B2 (en) 2016-01-06 2017-08-15 The Procter & Gamble Company Methods of forming a slurry with microcapsules formed from phosphate esters
US9732303B2 (en) 2016-01-06 2017-08-15 The Procter & Gamble Company Microcapsules formed from phosphate esters and compositions containing same
US9975255B1 (en) * 2016-12-15 2018-05-22 Jabil Inc. Apparatus, system and method for providing a conformable vacuum cup for an end effector
CN107417640B (zh) * 2017-02-22 2019-03-26 浙江大学 纳米噻唑锌的制备方法
CN107198677B (zh) * 2017-05-25 2021-07-09 长春金赛药业有限责任公司 黄体酮混悬型长效注射剂及其制备方法和黄体酮混悬注射粉针
KR102105872B1 (ko) * 2018-05-18 2020-04-29 강원대학교산학협력단 열용융압출법을 이용하여 제조된 구리 나노콜로이드 분산체 및 이의 용도
WO2019238261A1 (fr) 2018-06-15 2019-12-19 Ramirez Rios Liliana Patricia COMPLEXES MÉTALLIQUES DE β-DICÉTONES ET/OU DE POLYPHÉNOLS PAR CHIMIE VERTE, PROCÉDÉ DE PRÉPARATION, ÉCRAN SOLAIRE, CORRECTEUR DE TEINT DE LA PEAU OU DES CHEVEUX, TEINTURE CAPILLAIRE ET UTILISATIONS ASSOCIÉS
CN108904506A (zh) * 2018-07-27 2018-11-30 河南大华生物技术有限公司 一种地克珠利纳米粉末及其制备方法
CN108902480A (zh) * 2018-07-27 2018-11-30 河南大华生物技术有限公司 一种提高饲料中微量添加物均匀度和生物利用度的方法
AR116501A1 (es) * 2018-09-25 2021-05-12 Tolmar Int Ltd Sistema de suministro de polímero líquido para administración extendida de drogas
KR102359021B1 (ko) * 2019-07-29 2022-02-07 (주)케나프 가용성 플라보노이드 및 폴리페놀의 함량을 증진시키는 케나프 종자의 가공방법 및 이의 가공물
CN113133970A (zh) * 2020-01-17 2021-07-20 美国琛蓝营养制品股份有限公司 一种姜黄素复合物及其制备方法和检测方法
CN112674302A (zh) * 2021-01-07 2021-04-20 贵州山珍宝绿色科技开发有限公司 一种百香果刺梨果糕的制备方法
US20240033218A1 (en) * 2021-03-03 2024-02-01 Pulmatrix Operating Company, Inc. Dihydroergotamine dry powder formulations and methods of use
CN113729011A (zh) * 2021-07-30 2021-12-03 安徽瑞然生物药肥科技有限公司 草甘膦可溶粒剂及其生产方法
TW202320728A (zh) * 2021-11-04 2023-06-01 日商興和股份有限公司 醫藥品
TW202320776A (zh) * 2021-11-04 2023-06-01 日商興和股份有限公司 膠囊劑
CN114210995B (zh) * 2021-12-17 2023-03-10 浙江大学 一种利用牛蒡根提取液制备纳米银颗粒的方法、产品和应用
EP4209212A1 (fr) * 2022-01-05 2023-07-12 HWI pharma services GmbH Composition aqueuse comprenant des avermectines
CN114671704B (zh) * 2022-04-22 2023-04-18 广州粤瓷新材料有限公司 一种低膨胀多孔堇青石及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
JP4117811B2 (ja) * 1997-04-22 2008-07-16 日本化薬株式会社 フルタミド製剤及びその製法
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
ES2303527T3 (es) * 2000-05-10 2008-08-16 Jagotec Ag Procedimiento de molienda.
DE60137943D1 (de) 2000-08-31 2009-04-23 Jagotec Ag Gemahlene partikel
EP3269360A1 (fr) 2000-11-30 2018-01-17 Vectura Limited Procédé de fabrication de particules pour utiliser dans une composition pharmaceutique
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
KR20060024927A (ko) * 2004-09-15 2006-03-20 씨제이 주식회사 기계적 분쇄법에 의한 미크론 사이즈 인삼 분말의제조방법
CA2858733C (fr) * 2004-12-31 2017-12-19 Iceutica Pty Ltd Composition de nanoparticules et procedes de synthese de cette derniere
US20080245128A1 (en) 2005-02-08 2008-10-09 Ernest Comerford Method and Apparatus for Forming Metal Reinforcing
CA2631493A1 (fr) * 2005-12-15 2007-06-21 Acusphere, Inc. Procedes d'elaboration de preparations pharmaceutiques a base de particules pour administration pulmonaire ou nasale
JP2007169226A (ja) * 2005-12-22 2007-07-05 Ono Pharmaceut Co Ltd 固体分散体
US8420122B2 (en) * 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
US8808751B2 (en) * 2006-06-30 2014-08-19 Iceutica Pty Ltd. Methods for the preparation of biologically active compounds in nanoparticulate form
IN2014MN00380A (fr) * 2006-06-30 2015-06-19 Iceutica Pty Ltd
AR065802A1 (es) * 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
US8568696B2 (en) * 2008-08-06 2013-10-29 Indiana Nanotech Llc Grinding method for the manipulation or preservation of calcium phosphate hybrid properties
AU2010239160B2 (en) * 2009-04-24 2014-10-02 Iceutica Pty Ltd Method for improving the dissolution profile of a biologically active material
NZ595984A (en) * 2009-04-24 2014-04-30 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale

Also Published As

Publication number Publication date
IL215867A0 (en) 2012-01-31
CN102438593A (zh) 2012-05-02
WO2010121320A1 (fr) 2010-10-28
EP2421509B1 (fr) 2017-11-22
MX356518B (es) 2018-05-31
KR20150032759A (ko) 2015-03-27
IL254370B1 (en) 2023-08-01
CO6470805A2 (es) 2012-06-29
KR20160138326A (ko) 2016-12-02
US20180243707A1 (en) 2018-08-30
US20120165410A1 (en) 2012-06-28
IL254370A0 (en) 2017-11-30
ZA201108651B (en) 2013-01-30
AU2010239159A1 (en) 2011-11-10
US20170320030A1 (en) 2017-11-09
EA201171279A1 (ru) 2012-05-30
JP2012524716A (ja) 2012-10-18
EP2421509A1 (fr) 2012-02-29
UA110322C2 (uk) 2015-12-25
KR20120030384A (ko) 2012-03-28
CA2759102A1 (fr) 2010-10-28
AU2010239159B2 (en) 2014-06-12
EP2421509A4 (fr) 2013-01-09
JP2017101045A (ja) 2017-06-08
AP2011005993A0 (en) 2011-12-31
JP6141012B2 (ja) 2017-06-07
JP6534689B2 (ja) 2019-06-26
US20200316546A1 (en) 2020-10-08
CN105663045A (zh) 2016-06-15
KR101848766B1 (ko) 2018-05-28
AP3138A (en) 2015-02-28
AU2010239159C1 (en) 2014-10-16
MY159098A (en) 2016-12-15
EP3338766A1 (fr) 2018-06-27
NZ595973A (en) 2014-02-28
DK2421509T3 (en) 2018-02-26
US20150306556A1 (en) 2015-10-29
BRPI1014878A2 (pt) 2016-05-03
MX2011011230A (es) 2012-02-08
SG175309A1 (en) 2011-11-28
KR101743896B1 (ko) 2017-06-05
IL254370B2 (en) 2023-12-01

Similar Documents

Publication Publication Date Title
MA33297B1 (fr) Production de nanoparticules encapsulées à des fractions volumiques élevées
MA33292B1 (fr) Production de nanoparticules encapsulees a des fins commerciales
MA33299B1 (fr) Nouvelle formulation de naproxène
MA33294B1 (fr) Procédé destiné à la production de poudres de nanoparticules et de microparticules à usage commercial
MA33296B1 (fr) Nouvelle formulation d'indométhacine
MA33295B1 (fr) Nouvelle formulation de diclofénac
MA35567B1 (fr) Nouvelle formulation de méloxicam
MX2011011233A (es) Una formulacion novedosa de metaxalona.
BRPI0804820A2 (pt) formulações agroquìmicas dispersìveis em água
MA37524B1 (fr) Procedes de production de chlorhydrate d'anamoreline presentant une teneur en chlorure regulee
AU2014208310B2 (en) A Novel Formulation of Diclofenac
PH12015501811A1 (en) Production of encapsulated nanoparticles at high volume fractions
NZ710321A (en) Production of encapsulated nanoparticles at high volume fractions